

|               |            |
|---------------|------------|
| Fecha del CVA | 12/02/2020 |
|---------------|------------|

## Parte A. DATOS PERSONALES

|                                      |                       |      |  |
|--------------------------------------|-----------------------|------|--|
| Nombre y Apellidos                   | NOELIA MARTINEZ JAÑEZ |      |  |
| DNI/NIE/Pasaporte                    |                       | Edad |  |
| Núm. identificación del investigador | Researcher ID         |      |  |
|                                      | Scopus Author ID      |      |  |
|                                      | Código ORCID          |      |  |

### A.1. Situación profesional actual

|                       |                                   |                    |      |
|-----------------------|-----------------------------------|--------------------|------|
| Organismo             | Ramón y Cajal University Hospital |                    |      |
| Dpto. / Centro        |                                   |                    |      |
| Dirección             |                                   |                    |      |
| Teléfono              |                                   | Correo electrónico |      |
| Categoría profesional | Optional Area Specialist          | Fecha inicio       | 2007 |
| Espec. cód. UNESCO    |                                   |                    |      |
| Palabras clave        |                                   |                    |      |

### A.2. Formación académica (título, institución, fecha)

| Licenciatura/Grado/Doctorado              | Universidad                         | Año  |
|---|-------------------------------------|------|
| Programa Oficial de Doctorado en Medicina | Universidad Autónoma de Madrid      | 2017 |
| Graduate in medicine and surgery          | Autonomous University of Valladolid | 1998 |

### A.3. Indicadores generales de calidad de la producción científica

Total appointments: 88 Total appointments without own citations: 88 Average appointments / year: 22 (last 5 years) Total publications in the first quartile: 6 (4 first decile) Index h: 5

## Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Medical Oncologist of the Breast Unit and Gynecological tumors. Department of Medical Oncology. Ramón y Cajal University Hospital.

Bachelor of Medicine and Surgery from the University of Valladolid (1998). He continued studies at the Autonomous University of Madrid, specializing in Medical Oncology at La Paz Hospital (2003), with EXCELLENT level. In 2003, he obtained a master's degree in the treatment of support and palliative care in the cancer patient and in 2017 he was granted the title of Doctor, in Medical Oncology by the Autonomous University of Madrid, CUM LAUDE.

Since he finished his residency he has worked in different hospitals in the Community of Madrid, dedicating himself almost exclusively to breast cancer and since 2007, he is working in the Ramón y Cajal Hospital exclusively.

Author and co-author of several national and international publications focused on the treatment of breast cancer as well as principal investigator and co-investigator of numbers (> 40) national and international clinical trials.

## Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

### C.1. Publicaciones

- 1 Cortes, J.; et al. 2018. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. *Annals of oncology* : official journal of the European Society for Medical Oncology. ISSN 1569-8041.
- 2 ; et al. 2018. Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer *ONCOTARGET*.
- 3 Nuciforo, P.; et al. 2018. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. *Annals of oncology* : official journal of the European Society for Medical Oncology. 29-1, pp.170-177. ISSN 1569-8041.

- 4 Blancas, I.; et al. 2017. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. *Clinical & translational oncology* : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. ISSN 1699-3055.
- 5 Ciruelos, E.; et al. 2017. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. *Clinical & translational oncology* : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. ISSN 1699-3055.
- 6 Llombart Cussac, A.; et al. 2017. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. *The Lancet. Oncology*. 18-4, pp.545-554. ISSN 1474-5488.
- 7 Quintela Fandino, M.; et al. 2017. Critically short telomeres and toxicity of chemotherapy in early breast cancer. *Oncotarget*. 8-13, pp.21472-21482. ISSN 1949-2553.
- 8 Mestres, JA.; et al. 2017. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. *Clinical & translational oncology* : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 19-2, pp.149-161. ISSN 1699-3055.
- 9 N Martínez Jañez; et al. 2016. Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel *Breast Care*.
- 10 Martín, M.; et al. 2015. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology. 33-32, pp.3788-3883. ISSN 1527-7755.
- 11 González Martín, A.; et al. 2015. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. *Current cancer drug targets*. ISSN 1873-5576.
- 12 Gil Gil, MJ.; et al. 2015. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. *Breast cancer research and treatment*. 151-3, pp.597-1203. ISSN 1573-7217.
- 13 Manso, L.; et al. 2015. Use of bevacizumab as a first-line treatment for metastatic breast cancer. *Current oncology (Toronto, Ont.)*. 22-2, pp.e51. ISSN 1198-0052.

## C.2. Proyectos

### C.3. Contratos

- 1 A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor · Código de protocolo: CC-486-BRSTM-001 Noelia Martínez Jañez. Desde 2015.
- 2 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast. · Código de protocolo: INCB 18424-268 Noelia Martínez Jañez. Desde 2015.
- 3 Estudio fase 2 aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Farletuzumab (MORAb-003) en combinación con Carboplatino más Paclitaxel o Doxorubicina Liposómica Pegilada (PLD) en pacientes con cáncer de ovario sensible al platino bajo en CA-125. · Código de protocolo: MORAb-003-011. 2014-003812-36 Guerra. Desde 2015.
- 4 Estudio fase III, multicéntrico, abierto, aleatorizado, controlado para evaluar la eficacia y la seguridad de olaparib en monoterapia frente a la quimioterapia de elección del médico en el tratamiento de pacientes con cáncer de mama metastásico con mutaciones germinales de BRCA1/2. · Código de protocolo: D0819C00003 Noelia Martínez Jañez. Desde 2015.

- 5 Phase III Randomized Clinical Trial of Lubirectedin (PMO 1183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial) · Código de protocolo: PM1183-C-004-14.2014-005251-39 Guerra. Desde 2015.
- 6 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. (Diciembre 2014). · Código de protocolo: CO-338-014 Guerra. Desde 2014.
- 7 Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante negativo. (Noviembre 2014) · Código de protocolo: Código del ensayo D081CC00006. Número del ensayo BIG 6-13, NSABP B-55 Noelia Martínez Jañez. Desde 2014.
- 8 A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer. M Código de protocolo: 2013-001110-15 Desde 2013.
- 9 Estudio de Fase 2, aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la eficacia y seguridad de la enzalutamida en combinación con exemestano, en pacientes con cáncer de mama avanzado, receptor de estrógeno o progesterona positivo y HER2 negativo." · Código de protocolo: MDV3100-12 Noelia Martínez Jañez. Desde 2012.
- 10 Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3ª línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o localmente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE" (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin) · Código de protocolo: ONCOSUR 2012-02 Noelia Martínez Jañez. Desde 2012.
- 11 Ensayo fase II randomizado para la caracterización de la neurotoxicidad de Nab-paclitaxel versus paclitaxel convencional en primera línea de cáncer de mama metastásico her2-negativo. Código de protocolo: ONCOSUR 2012-01. NEURABRAX Desde 2012.
- 12 Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3ª línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o localmente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE" (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin). · Código de protocolo: ONCOSUR 2012-02 Noelia Martínez Jañez. Desde 2012.

#### C.4. Patentes